Valneva’s Vaccination Valor: A Buy Rating Justified (OTCMKTS:INRLF)

Boy Receiving a Vaccination


Reason for the update: earnings and clinical catalysts

This article is a revisit of Valneva (OTCPK:INRLF) (NASDAQ:VALN) with a) updated analysis on Q2 2023 results and b) upcoming catalysts (vaccine PDUFA) that we find material for the stock’s price action as we

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *